Introduction

CD8
+ cytotoxic T lymphocytes (CTLs) are the central component of the host adaptive immune system. A typical CD8 + T cell immune response starts from T cell receptor (TCR) recognition of cognate antigenic peptides presented by the MHC class I molecule. The interaction between the TCR and the antigen-MHC class I complex, in coordination with costimulatory signals delivered by interactions between costimulatory receptor CD28 on T cells and costimulatory ligands B7.1 and/or B7.2 on antigen-presenting cells (APCs), induces CD8 + T cell activation (1) (2) (3) . However, T cell-mediated cytotoxicity must spare destruction of normal cells and maintain self-tolerance, which is accomplished by several corepressive mechanisms and also through receptor-ligand interactions between CD8 + T cells and APCs. The major corepressive receptor, programmed cell death protein 1 (PD-1), interacts with programmed cell death protein 1 ligand 1 (PD-L1) and/or PD-L2 expressed by APCs (4-6), resulting in dephosphorylation of both CD28 and TCR and repression of T cell activation (4, (7) (8) (9) . In addition, CTLA-4, LAG-3, and TIM-3 also act as corepressive receptors to keep chronically activated effector T cells in check (10) . These corepressive receptors thus function as immune checkpoints to maintain the balance during the CD8 + T cell adaptive immune response. CTLs are the primary immune cells that act to eradicate tumors (11, 12) . On one hand, CTLs recognize tumor cells through tumor-specific antigens to mount an antitumor immune response and suppress tumor progression. However, tumor cells often mount a counterattack by multiple mechanisms including loss of antigen expression, and both primary and acquired resistance mechanisms, which in turn shut down the tumor-reactive CTLs in the tumor microenvironment (13) (14) (15) (16) . Therefore, tumor cells hijack the corepressive receptor-based immune checkpoint mechanism to suppress tumor-reactive CTLs to avoid immune rejection (17) (18) (19) (20) . Based on this mechanism, antibody-based inhibitors to block CTLA-4 and PD-1/PD-L1 immune checkpoints have been developed and shown durable efficacy in many types of human cancers (21) (22) (23) . However, not all human cancers respond to these ICI immunotherapies and a large fraction of patients in the responsive cancer types also do not respond favorably. This clinical conundrum suggests that there may exist other immune checkpoints that suppress CTL function in tumor rejection. We aimed to test this hypothesis and observed that interferon regulatory factor 8 (IRF8) functions as a repressor of osteopontin (OPN) expression and loss of IRF8 expression in CD11b + Ly6C lo Ly6G + myeloid cells and colon tumor cells leads to elevated expression of OPN that acts as a potent T cell suppressor. Our data demonstrate that IRF8 regulates T cell activation through repressing OPN expression, and myeloid and tumor cells use the silencing of IRF8 expression to upregulate the expression of OPN, which functions as an immune checkDespite breakthroughs in immune checkpoint inhibitor (ICI) immunotherapy, not all human cancers respond to ICI immunotherapy and a large fraction of patients with the responsive types of cancers do not respond to current ICI immunotherapy. This clinical conundrum suggests that additional immune checkpoints exist. We report here that interferon regulatory factor 8 (IRF8) deficiency led to impairment of cytotoxic T lymphocyte (CTL) activation and allograft tumor tolerance. However, analysis of chimera mice with competitive reconstitution of WT and IRF8-KO bone marrow cells as well as mice with IRF8 deficiency only in T cells indicated that IRF8 plays no intrinsic role in CTL activation. Instead, IRF8 functioned as a repressor of osteopontin (OPN), the physiological ligand for CD44 on T cells, in CD11b
Ly6G
+ myeloid cells and OPN acted as a potent T cell suppressor. IRF8 bound to the Spp1 promoter to repress OPN expression in colon epithelial cells, and colon carcinoma exhibited decreased IRF8 and increased OPN expression. The elevated expression of OPN in human colon carcinoma was correlated with decreased patient survival. Our data indicate that myeloid and tumor cell-expressed OPN acts as an immune checkpoint to suppress T cell activation and confer host tumor immune tolerance. matricellular protein that also acts as the physiological ligand for CD44 (29) . qPCR analysis revealed that total spleen cells from IRF8-KO mice expressed a more than 10-fold higher level of OPN than WT spleen cells ( Figure 3A + T cell activation and proliferation in a dosedependent manner ( Figure 4, A and B) . Consistent with the inhibited T cell proliferation, OPN inhibited IFN-γ production by T cells in vitro ( Figure 4C ). To determine whether OPN inhibits T cell activation, we analyzed T cell activation markers. OPN decreased CD69 + CD8
+ T cells as early as 2 hours after stimulation ( Figure  4D) . Similarly, the levels of CD25-and PD-1-expressing CD8 + T cells were also decreased by OPN ( Figure 4D (31) . We first analyzed the development of mature T cells 8 weeks after transplantation. Although it has been reported that the point to suppress CTL activation to promote host tumor immune tolerance and tumor immune evasion.
Results
IRF8 null mice tolerate allograft tumor. 4T1 tumor cells, a mouse tumor cell line of BALB/c origin, were orthotopically injected into the mammary gland of WT C57BL/6 mice and IRF8 knockout (IRF8-KO) mice of C57BL/6 origin. 4T1 tumors grew initially in the WT C57BL/6 mice, but were quickly rejected within 2 weeks after tumor transplant (Figure 1, A and B) . Surprisingly, 4T1 tumors continued growing and formed relatively large tumors in all IRF8-KO mice (Figure 1, A and B) .
IRF8-deficient mice are deficient in generation of antigen-specific CD8 + T cells. Allograft rejection is mediated by host T cells (24) . The above observations thus suggest that IRF8 deficiency might lead to T cell functional deficiency in the IRF8-KO mice (25) . To test this hypothesis, we made use of the ovalbumin (OVA) peptide vaccination system to determine IRF8 function in T cell response to antigen in vivo. WT and IRF8-KO mice were vaccinated with OVA peptide to activate CD8 + T cells. As expected, WT mice responded to the OVA peptide robustly to generate OVA-specific CD8 + T cells ( Figure 1 , C-E). In contrast, IRF8-KO mice exhibited a significantly decreased response to generate OVA-specific CD8 + T cells (Figure 1 , D and E). A complementary approach was then taken to validate this finding. IRF8-KO chimera mice with IRF8 deficiency only in hematopoietic cells, and control WT chimera mice were vaccinated with the OVA vaccine. The WT chimera mice responded efficiently as determined by generation of OVA-specific CD8 + T cells ( Figure 1F) . Consistent with what was observed in IRF8-KO mice, the IRF8-KO chimera mice also generated significantly fewer OVA-specific CD8 + T cells (Figure 1 , F and G). Our data thus indicate that global deletion of Irf8 in mice leads to deficiency in the generation of antigen-specific CD8 + T cells in vivo.
IRF8-deficient CD8
+ T cells have a CD44 hi memory T cell phenotype. To identify the cellular mechanisms underlying why IRF8-deficient CD8 + T cells fail to be activated in response to antigen in vivo, we performed flow cytometric analysis of cell surface markers on CD8 + T cells comparing those from WT to IRF8-KO mice and identified that the CD44 level is markedly different between the 2 populations ( Figure 2, A and B) . The percentage of the subset of CD44 hi cells is significantly higher on CD8 + T cells in lymphoid organs of IRF8-KO mice compared with WT mice ( Figure 2C ).
IRF8 regulates OPN expression in myeloid cells. CD44 is known to interact with various ligands, which are crucial for its cellular function (26, 27) . The above observation that IRF8 deficiency leads to significantly increased CD44 hi CD8 + T cells in mice suggests that CD44 may contribute to the deficiency of CD8 + T cell activation. To test this hypothesis, we first analyzed the expression level of major CD44 ligands in spleen cells. Hyaluronic acid is considered the major ligand for CD44 (28) . Quantitative polymerase chain reaction (qPCR) analysis of total spleen cells indicated that the expression levels of the major genes encoding enzymes of the hyaluronic acid metabolism pathways, including Figure 5E ). There is no significant difference in the percentage of OVA-specific WT and Irf8 -/-CD8 + T cells ( Figure 5F ).
Antigen-specific CD8 + T cell differentiation and allograft tumor tolerance is independent of intrinsic IRF8 function in T cells.
A complementary approach was then used to strengthen our above finding that the deficiency in generation of antigen-specific CD8 
CD8
+ cells were gated for OVA tetramer + cells. Naive C57BL/6 mice were used as negative and gating controls (C). FSC-A, forward scatter-area. Shown are representative plots of one pair of WT and IRF8-KO mice from 1 of 2 independent experiments (D). The tetramer + CD8 + T cells were quantified (E). (F) WT C57BL/6 and IRF8-KO BM cells were adoptively transferred into lethally irradiated C57BL/6 recipient mice to recreate chimera mice with IRF8 deficiency only in the hematopoietic cells. The chimera WT (n = 4) and IRF8-KO (n = 3) mice were vaccinated as in A-C and analyzed for OVA-specific CD8 + T cells. Shown are representative plots from one pair of mice. (G) Quantification of OVA-specific CD8 + T cells in WT and IRF8-KO chimera mice. jci.org Volume 128
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was observed in IRF8-KO mice that tolerate the allograft 4T1 tumor (Figure 1 ), IRF8-TKO mice rejected the allograft 4T1 tumor completely ( Figure 6F ). Taken together, these data demonstrate that IRF8 regulates antigen-specific CD8 + T cell activation and allograft tumor tolerance in a cell-extrinsic manner, and myeloid cell-expressed OPN may suppress CD8 + T cell activation in vivo. IRF8 functions as either a transcriptional activator or repressor depending on its associated protein factors and the target gene promoter consensus sequence (34) . We analyzed the mouse Spp1 gene promoter and identified 2 putative IRF8 consensus interferon-stimulated response elements (ISRE1 and ISRE2) (Figure 7E) . Analysis of normal colon tissues by chromatin immunoprecipitation (ChIP) detected IRF8 association with the ISRE consensus sequence chromatin at the Spp1 promoter region ( Figure 7F ). As a complementary approach, electrophoretic mobility shift assay (EMSA) was then used to determine IRF8 binding to the 2 putative ISRE elements of the Spp1 promoter. IRF8-specific antibody did not supershift the IRF8-DNA complexes when nuclear extracts from the colon were used. To determine the specific colon epithelial cell IRF8 protein complex-DNA interaction, we used a cold DNA probe competition approach. A DNA probe containing the ISRE consequence sequence element of the mouse Pdcd1 promoter (Supplemental Table 1 ) was incubated with nuclear extracts from activated CD3 + T cells. Two protein-DNA complexes were detected and anti-IRF8 antibody displaced them ( Figure 7G ), indicating IRF8 binding to this DNA probe. We next used the Pdcd1 promoter ISRE-containing DNA probe to compete the Spp1 promoter ISRE probes. Two major protein-DNA complexes were detected when colon nuclear extract was incubated with Spp1 ISRE1 and ISRE2 DNA probes ( Figure 7G ) and cold Pdcd1 ISRE DNA probe competed away the 2 protein-DNA complexes ( Figure 7H ). These observations determined that IRF8 protein binds to the ISRE elements at the Spp1 promoter to repress OPN expression in colon epithelial cells. ferent between IRF8-TKO and WT mice ( Figure 6B ). Consistent with the normal CD44 and OPN expression patterns, IRF8-TKO mice responded to OVA peptide vaccination in a similar degree as the WT mice in the generation of OVA-specific CD8 + T cells ( Figure  6, C and D) .
To determine whether IRF8-TKO mice tolerate an allograft tumor, 4T1 tumor cells were injected into IRF8-TKO mice. 4T1 tumor cells were also injected into WT BALB/c mice as an autograft tumor control. As expected, the 4T1 tumor grew aggressively in syngeneic BALB/c mice ( Figure 6E ). However, unlike what also significantly inhibited IFN-γ secretion by human CD8 + T cells ( Figure 8F ). Taken together, our data indicate that OPN is an inhibitor of human CD8 + T cells and OPN expression is elevated in human colon cancer and secreted into the periphery. OPN promotes human colon cancer progression.
Discussion
T cell activation, particularly the transition from the resting stage of naive T cells to the functional effector phase of CD8 + cytotoxic T cells, requires marked changes in gene expression, which is regulated by T cell-specific transcription factors (35) . In addition to the well-characterized T-box transcription factor (T-bet) and eomesodermin (Eomes) (36, 37) , IRF8 has recently emerged as another key transcription factor that regulates CD8 + T cell activation and differentiation (38) . IRF8 was previously identified as a lineage-specific transcription factor for myeloid cell differentiation. Mice with a null mutation of IRF8 exhibit massive accumulation of CD11b + Gr1 + immature myeloid cells, revealing an essential role of IRF8 in myelopoiesis (32) . IRF8 regulates myeloid cell differentiation through repressing granulocyte development and promoting differentiation of monocytic cells such as dendritic cells and macrophages (39) (40) (41) (42) (43) . IRF8 functions in hematopoietic cell differentiation and activation have since been extended to other hematopoietic cells, including B, NK, and T cells (25, 31, 41, (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) . However, IRF8 functions in T cells are apparently tissue-and disease-specific (25, 30, 38, 46, 53, 57) . The mechanism underlying IRF8 function in regulation of T cell activation is largely unknown. Here, we determined that the intrinsic IRF8 function is not required for T cell activation, and that IRF8 regu-OPN is elevated in human colon cancer patient periphery and is correlated with decreased disease-specific survival. To determine whether the above findings can be translated to human colon cancer patients, mRNA expression data sets of colon cancer and matched normal tissues were extracted from The Cancer Genome Atlas (TCGA) data sets. IRF8 expression level is significantly downregulated in human colon carcinoma as compared with normal colon, whereas OPN expression is significantly upregulated in human colon carcinoma as compared with the normal colon ( Figure 8A ). As OPN is a secreted protein, it is therefore possible that OPN protein level may be elevated in patient periphery. To test this hypothesis, we analyzed serum specimens from healthy donors and patients with colon cancer. As expected, OPN protein level is significantly higher in serum from patients with colon cancer as compared with healthy donors ( Figure 8B ). We determined that OPN is a potent suppressor of CD8 + T cells (Figure 4 , A and B) and CD8 + T cells are the primary adaptive immune cells of the host cancer immunosurveillance. It is thus likely that elevated OPN will decrease host cancer immunosurveillance to promote tumor progression. To test this hypothesis, we analyzed OPN expression level and colon cancer patient clinical outcomes. Indeed, Kaplan-Meier survival analysis revealed that OPN expression level is inversely correlated with survival time of patients with colon cancer ( Figure  8C ). To determine whether OPN inhibits human CD8 + T cell activation, human T cells were activated with anti-CD3 mAb in the absence or presence of recombinant human OPN protein. Analysis of cellular proliferation indicated that OPN significantly inhibited human CD8 + T cell proliferation at a concentration of 5 μg/ml (Figure 8, D and E) . Consistent with the decreased proliferation, OPN IRF8 is an essential lineage-specific transcription factor for myeloid cell differentiation (41) , and IRF8 deficiency leads to impaired differentiation of myeloid cells, including plasmacytoid dendritic cells (pDCs), CD8α + conventional DCs, and CD103 + DCs (39, 40, 49, 58) . IRF8-KO mice are deficient in the generation of effector T cells in both the EAE and the experimental graft-versus-host disease (GVHD) mouse models (57, 59) , but the underlying mechanism is unknown. In this study, we observed that IRF8-KO mice do not respond to antigenic stimulation to generate antigen-specific effector CD8 + T cells. Therefore, it is possible that IRF8 deficiency may diminish APCs to impair host immune responses to generate antigen-specific T cells in vivo. Analysis of APCs in IRF8-KO mice revealed that although the levels of several subsets of APCs are decreased, IRF8-KO mice still have substantial levels of conventional DCs, CD8α-DCs, and CD8a + DCs (Supplemental Figure 3) . Furthermore, IRF8-KO mice exhibited enhanced expansion of Th17 cells and developed more severe inflammation in the experimental colitis mice (46) , suggesting that IRF8-KO mice do have functional APCs and are capable of generating effector T cells. Therefore, although IRF8 deficiency may decrease the levels of certain APC populations, a decreased level of APCs is unlikely the main cause of impairment of CD8 + T cell activation and immune tolerance against allograft tumor challenge in IRF8-KO mice.
IRF8 is not expressed in naive T cells, but is rapidly induced by T cell receptor (TCR) stimulation and γc-cytokine (30, 59) , suggesting a role of IRF8 in T cell activation and differentiation. Indeed, knocking out IRF8 abrogated naive CD8 + T cell differen- + T cells were cultured in plates coated with anti-CD3 (0.8 μg/ml) and anti-CD28 (10 μg/ml) mAbs and OPN at the indicated concentrations in triplicate for 3 days. Culture supernatant was collected and measured for IFN-γ protein level by ELISA. Data from B and C were analyzed using a 1-way ANOVA, with Dunnett's test for multiple comparisons. (D) CD3 + T cells were cultured in plates coated with anti-CD3 (0.8 μg/ml) and anti-CD28 (10 μg/ml) mAbs in the presence of IgG (5 μg/ml) or OPN (1 μg/ml and 5 μg/ml, respectively). Cells were collected at the indicated time points, stained with CD69-, CD25-, PD-1-, and CD8-specific mAbs, and analyzed by flow cytometry. Data are mean ± SD. Significance was calculated using a 2-way ANOVA with Tukey's test. jci.org
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tiation into effector cells in the experimental GVHD mouse model (59) . Furthermore, in the EAE mouse model, while all WT mice responded to myelin oligodendrocyte glycoprotein (MOG) peptide vaccination and showed clear signs of EAE, IRF8-KO mice showed no signs of response to MOG vaccination and were completely resistant to EAE in the absence of effector T cells (57) . In this study, we observed that IRF8-KO mice tolerated an allograft tumor challenge. Furthermore, we observed that naive CD8 + T cells do not respond to antigen stimulation to generate antigenspecific CD8
+ effector T cells. Our observations thus support the notion that IRF8 is essential for CD8 + T cell activation and effector function (46, 57, 59) and determined a critical role of IRF8 in T cell-mediated immune surveillance. However, strikingly, competitive reconstitution of WT and Irf8 -/-BM revealed that intrinsic IRF8 function is not required for naive CD8 + T cell response to antigen to differentiate into antigen-specific CD8 + effector cells, suggesting a CD8 + T cell-extrinsic mechanism that underlies IRF8 function in regulating naive CD8 + T cell activation and differentiation in vivo. This notion was further supported by our observation that IRF8-TKO mice respond to antigenic stimulation and reject allograft tumors as efficiently as WT mice. We believe we have therefore identified a previously uncharacterized mechanism that IRF8 regulates CD8 + T cell activation through a cell-extrinsic mechanism. More importantly, we have identified the molecular link between myeloid cells and T cells in the context of IRF8 function in T cell activation. We demonstrated that OPN is a potent suppressor of T cell activation and its expression is repressed by IRF8 in myeloid cells. In the absence of IRF8, OPN is highly expressed in CD11b + Ly6C lo
Ly6G
+ myeloid cells under physiological conditions. IRF8 therefore acts as a repressor of OPN expression in myeloid cells to facilitate T cell activation in a cell-extrinsic mechanism. Our data indicate that OPN functions as a repressive ligand that negatively regulates T cell activation.
However, OPN is known to be markedly elevated after irradiation and persistent throughout the course of GVHD (60) . OPN apparently acts to enhance activation and survival of T cells during GVHD (60, 61) . The mechanism underlying these contrasting functions of OPN in GVHD and cancer is unknown and thus requires further study.
Although IRF8 was originally identified and extensively studied in myeloid cells (62) , IRF8 is also expressed and functional in nonhematopoietic cells (63, 64) and acts as a tumor suppressor (65, 66) . Interestingly, we observed that the highly expressed IRF8 binds to the Spp1 promoter region to repress OPN expression in colon epithelial cells. However, IRF8 expression is silenced and OPN is elevated during colon epithelial cells transformation into colon tumor cells, suggesting that tumor cells may use downregulation of IRF8 to upregulate OPN as a mechanism to suppress host CTL antitumor immune response. We believe, therefore, that our data revealed a previously uncharacterized mechanism of action of IRF8 as a tumor suppressor and indicate that IRF8 acts to repress OPN to suppress OPN-mediated immune suppression to suppress tumor development. Elevated OPN expression is known to link to the progression of colon cancer and multiple other human cancers (67, 68) . Our data indicate that OPN is highly expressed in CD11b + Ly6C lo Ly6G + myeloid cells and tumor cells, 2 major components of the tumor microenvironment. Therefore, OPN may act as another immune checkpoint and contribute, at least in part, to CTLA-4/PD-1/ PD-L1-independent immune suppression and cancer patient nonresponse to the current ICI immunotherapy.
Methods
Mice. IRF8-KO mice were generated as previously described (32 /J) were generated as previously described (30) . WT and IRF8-KO chimera mice were created by transferring 5 × 10 6 to 10 × 10 6 BM cells from C57BL/6
and IRF8-KO mice to lethally (8.5 Gy) radiated C57BL/6 recipient mice, respectively. To create mixed BM chimera mice, C57BL/6 and SJL mice were crossed to generate F1 hybrid mice. BM cells from SJL and IRF8-KO mice were then mixed (at 1:2 or 1:5 ratio of SJL/IRF8- KO) and adoptively transferred to the lethally radiated F1 hybrid mice to generate mixed chimera mice (Supplemental Figure 3) . Mouse tumor model. Mice were injected with AOM (Sigma-Aldrich, 10 mg/kg body weight) intraperitoneally once and treated with 2.5% DSS (MP Biomedicals, 35,000-50,000 mol wt) 1 day after AOM injection for 1 week, followed by 2 weeks with sterile, untreated water. The AOM-DSS cycle was repeated 2 more times. Mice were maintained with regular drinking water after the third AOM-DSS cycle and sacrificed for analysis. 4T1 mammary carcinoma cells were obtained from American Type Culture collection (ATCC). 4T1 cells were tested for mycoplasma and were mycoplasma-free at the time of the study. 4T1 tumor cells (1 × 10 4 cells/mouse) were injected into the no. 3 mammary gland of female BALB/c mice.
Human colon carcinoma data set and peripheral blood specimens. The gene expression data set was extracted from the TCGA Colon and Rectal Cancer (COADREAD) data set using the Xena Functional Genomics Explorer (UCSD). Human colon cancer patient serum was obtained from the Georgia Cancer Center Biorepository (Augusta, GA). Human blood specimens were obtained with written informed consent from healthy donors enrolled in the Shepeard Community Blood Bank (Augusta, GA).
GFP fluorescence visualization. GFP fluorescence was visualized as previously described (30) . The tissues were then examined under a LSM780 Meta confocal laser microscope (Carl Zeiss). The captured images were viewed and analyzed using Zeiss Zen Meta imaging 2012 software.
Activation of CD8 + T cells by vaccination in vivo.
Mice were given immunizations with the OVA peptide (SIINFEKL) using the reported procedures (69) . The vaccine consists of a prime followed by a boost 14 days later, and is administered by injecting a mixture of the OVA peptide (100 μg, Genscript), CD40 mAb (prime 100 μg, boost 25 μg; + T cells were stimulated on anti-CD3-and anti-CD28-coated plates for 3 days. Nuclear extracts were prepared and analyzed for IRF8 binding by using EMSA with the Pdcd1 promoter ISRE consensus sequence DNA probe (Supplemental Table 1 ). Anti-IRF8 antibody was used to identify the IRF8-DNA complexes. IgG was used as a negative control. Red arrows point to the IRF8-Pdcd1 ISRE DNA complexes. (H) Nuclear extract was prepared from normal mouse colon and incubated with the 2 ISRE DNA probes as shown in D. The unlabeled Pdcd1 ISRE DNA probe (cold probe) was used at the indicated amount (fold over the labeled Spp1 ISRE probes) to compete the Spp1 IRRE probes. Green arrow points IRF8-DNA complex. jci.org Volume 128
Number 12 sis was calculated using a log-rank test on a Cox hazard-proportional model. Significance for activation marker kinetics was calculated using a 2-way ANOVA with Tukey's test. Significance for IFN-γ production and division index was calculated using a 1-way ANOVA with Dunnett's correction. Tumor volume was calculated as (length × width 2 )/2. P less than 0.05 was considered statistically significant. All data are mean ± SD.
Study approval. Use of mice was performed according to protocol 2008-0162 approved by the Augusta University institutional animal use and care committee. All studies with human specimens were reviewed and determined as "not human subject research" by the Augusta University Institutional Review Board (approval 933148-1).
